The 21 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 142.00, with a high estimate of 161.00 and a low estimate of 120.00. The median estimate represents a +21.87% increase from the last price of 116.52.
The current consensus among 24 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.07
Reporting Date Oct 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.